ArcticZymes Technologies ASA (LTS:0DRV)
kr 13.34 0 (0%) Market Cap: 676.18 Mil Enterprise Value: 443.00 Mil PE Ratio: 167.50 PB Ratio: 2.15 GF Score: 65/100

Q2 2019 Biotec Pharmacon ASA Earnings Call Transcript

Aug 15, 2019 / 06:30AM GMT
Release Date Price: kr4.29
Christian JÃ;rgensen
Biotec Pharmacon ASA - CEO

¸ -

Good morning, everybody. Good morning to the shareholders here in Oslo. And good morning to everybody who is listening on the webcast here today. Also, I'd like to introduce CFO, Børge Sørvoll, who will be here together with me today to present our second quarter results for Biotec Pharmacon.

The agenda is like it is always. We'll go through some highlights for Q2. We'll spend some time with our ArcticZymes business. We'll spend some time talking about the BetaGlucan business. Then Børge will come on the podium and will run you through the financials, and I will come back and discuss the outlook for 2019. Questions, of course, are always welcome, and we will see if we can answer them. We also have possibilities to answer your questions on the Web. So if anybody is listening in and having a question to ask, we have facilities so we can take those questions on the Web and answer them here.

This is a slide that we show every time we are presenting ourselves. It's just the basis of what we are and why do we have these 2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot